The triple drug regimen of steroid (dexamethasone), a serotonin 5-HT₃ receptor antagonist (RA), and a neurokinin 1 (NK1) receptor antagonist has been studied for prevention and management of CINV in patients with cancer receiving multiday chemotherapy regimens. This combination has been recommended by National Comprehensive Cancer Network (NCCN) for patients receiving high emetic risk IV chemotherapy.